Suppr超能文献

血管生成抑制剂 Isthmin-1(ISM1)在肾小球病的实验模型中过度表达,并损害足细胞的活力。

The Angiogenesis Inhibitor Isthmin-1 (ISM1) Is Overexpressed in Experimental Models of Glomerulopathy and Impairs the Viability of Podocytes.

机构信息

Sorbonne Université, UMR_S 1155, 75006 Paris, France.

Institut National de la Santé et de la Recherche Médicale UMR_S 1155, 75020 Paris, France.

出版信息

Int J Mol Sci. 2023 Feb 1;24(3):2723. doi: 10.3390/ijms24032723.

Abstract

Focal segmental glomerulosclerosis (FSGS) is a major cause of end-stage renal disease and remains without specific treatment. To identify new events during FSGS progression, we used an experimental model of FSGS associated with nephroangiosclerosis in rats injected with L-NAME (N-nitro-L-arginine methyl ester). After transcriptomic analysis we focused our study on the role of Isthmin-1 (ISM1, an anti-angiogenic protein involved in endothelial cell apoptosis. We studied the renal expression of ISM1 in L-NAME rats and other models of proteinuria, particularly at the glomerular level. In the L-NAME model, withdrawal of the stimulus partially restored basal ISM1 levels, along with an improvement in renal function. In other four animal models of proteinuria, ISM1 was overexpressed and localized in podocytes while the renal function was degraded. Together these facts suggest that the glomerular expression of ISM1 correlates directly with the progression-recovery of the disease. Further in vitro experiments demonstrated that ISM1 co-localized with its receptors GRP78 and integrin αvβ5 on podocytes. Treatment of human podocytes with low doses of recombinant ISM1 decreased cell viability and induced caspase activation. Stronger ISM1 stimuli in podocytes dropped mitochondrial membrane potential and induced nuclear translocation of apoptosis-inducing factor (AIF). Our results suggest that ISM1 participates in the progression of glomerular diseases and promotes podocyte apoptosis in two different complementary ways: one caspase-dependent and one caspase-independent associated with mitochondrial destabilization.

摘要

局灶节段性肾小球硬化症(FSGS)是终末期肾病的主要病因,目前尚无特效治疗方法。为了明确 FSGS 进展过程中的新事件,我们利用 L-NAME(N-硝基-L-精氨酸甲酯)诱导的大鼠 FSGS 伴肾血管硬化模型进行了转录组分析。在分析后,我们将研究重点放在了伊斯特明-1(ISM1,一种参与内皮细胞凋亡的抗血管生成蛋白)上。我们研究了 ISM1 在 L-NAME 大鼠和其他蛋白尿模型中的肾脏表达,尤其是在肾小球水平上。在 L-NAME 模型中,撤去刺激源会部分恢复基础 ISM1 水平,并改善肾功能。在其他四种蛋白尿动物模型中,ISM1 过表达并定位于足细胞,同时肾功能下降。这些事实表明,肾小球中 ISM1 的表达与疾病的进展和恢复直接相关。进一步的体外实验表明,ISM1 与其在足细胞上的受体 GRP78 和整合素 αvβ5 共定位。用低浓度重组 ISM1 处理人足细胞会降低细胞活力并诱导半胱天冬酶激活。足细胞中更强的 ISM1 刺激会降低线粒体膜电位并诱导凋亡诱导因子(AIF)的核转位。我们的研究结果表明,ISM1 参与了肾小球疾病的进展,并通过两种不同的互补方式促进足细胞凋亡:一种是半胱天冬酶依赖性的,另一种与线粒体不稳定相关的半胱天冬酶非依赖性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f80/9916724/71399b6289de/ijms-24-02723-g001a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验